{"nctId":"NCT02582814","briefTitle":"The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM","startDateStruct":{"date":"2015-10-26","type":"ACTUAL"},"conditions":["Type 1 Diabetes Mellitus"],"count":151,"armGroups":[{"label":"dapagliflozin 5mg + insulin","type":"EXPERIMENTAL","interventionNames":["Drug: Dapagliflozin 5 mg"]},{"label":"dapagliflozin 10mg + insulin","type":"EXPERIMENTAL","interventionNames":["Drug: Dapagliflozin 10mg"]}],"interventions":[{"name":"Dapagliflozin 5 mg","otherNames":[]},{"name":"Dapagliflozin 10mg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Signed Written Informed Consent\n* Diagnosis of T1DM. In addition, the following criteria also needs to be met; Central laboratory test of C-peptide \\< 0.7 ng/mL\n* Insulin use for at least 12 months prior to the enrolment per subject report or medical records and Method of insulin administration (MDI or CSII) must have been unchanged for at least 3 months prior to the enrolment per subject report or medical records. Subjects must be taking a total daily insulin dose of ≥ 0.3 U/kg/day for at least 3 months prior to the enrolment. If on MDI insulin administration subject must be on ≥ 3x injections per day.\n* Japanese men and women\n* Screening Visit: Central laboratory HbA1c ≥ 7.5% and ≤ 10.5%\n* BMI ≥ 20.0 kg/m² at visit 1\n* Age 18 to 75 years, inclusive\n\nExclusion Criteria:\n\n\\- Target Disease Exceptions History of T2DM Maturity onset diabetes of young (MODY) Any anti-hyperglycemic agent use, other than α-GI or insulin, within 1 month prior to the enrolment.\n\nUse of thiazolidinediones within 6 months prior to the enrolment History of DKA requiring medical intervention within 1 month prior to the enrolment History of hospital admission for glycemic control (either hyperglycemia or hypoglycemia) within 1 month prior to the enrolment\n\n* Medical History and Concurrent Diseases Malignancy within 5 years of the enrolment (with the exception of treated basal cell or treated squamous cell carcinoma) History of bladder cancer History of radiation therapy to the lower abdomen or pelvis at any time\n* Physical and Laboratory Test Findings Aspartate aminotransferase (AST) \\> 3x upper limit of normal (ULN) Alanine aminotransferase (ALT) \\> 3x ULN Serum total bilirubin (TB) \\> 2.0 mg/dL (34.2 μmol/L) Estimated GFR (eGFR) by the Japanese Society of Nephrology formula ≤ 45 mL/min/1.73m2 Hemoglobin ≤ 11.0 g/dL (110 g/L) for men; hemoglobin ≤ 10.0 g/dL (100 g/L) for women.\n\nPositive for hepatitis B surface antigen or anti-hepatitis C virus antibody Abnormal Free T4","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Adverse Event Summary","description":"To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Hypoglycemia","description":"To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"PRIMARY","title":"Diabetic Ketoacidosis (DKA)","description":"To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Change From Baseline in HbA1c","description":"To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.52","spread":null},{"groupId":"OG001","value":"-0.66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.33","spread":null},{"groupId":"OG001","value":"-0.36","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Percent Change From Baseline in Total Daily Insulin Dose","description":"To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.30","spread":null},{"groupId":"OG001","value":"-15.14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.27","spread":null},{"groupId":"OG001","value":"-13.13","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Percent Change From Baseline in Body Weight","description":"To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.88","spread":null},{"groupId":"OG001","value":"-5.26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.25","spread":null},{"groupId":"OG001","value":"-5.96","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Change From Baseline in Glycoalbumin","description":"To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.26","spread":null},{"groupId":"OG001","value":"-2.63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.49","spread":null},{"groupId":"OG001","value":"-1.68","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Change From Baseline in Average Daily Glucose Measured by 6-point SMBG","description":"To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.37","spread":null},{"groupId":"OG001","value":"-15.06","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.62","spread":null},{"groupId":"OG001","value":"-12.93","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Change From Baseline in Post-prandial Glucose Measured by 6-point SMBG","description":"To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.33","spread":null},{"groupId":"OG001","value":"-10.08","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.40","spread":null},{"groupId":"OG001","value":"-5.24","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects Achieving HbA1c Reduction of 0.5 Percent Without Severe Hypoglycemia","description":"To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.8","spread":null},{"groupId":"OG001","value":"61.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.4","spread":null},{"groupId":"OG001","value":"41.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects Achieving HbA1c Reduction of 0.5 Percent","description":"To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.2","spread":null},{"groupId":"OG001","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.4","spread":null},{"groupId":"OG001","value":"45.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects Achieving HbA1c < 7.0 Percent","description":"To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.5","spread":null},{"groupId":"OG001","value":"5.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":null},{"groupId":"OG001","value":"2.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Change From Baseline in SBP in Subjects With Baseline SBP/DBP >= 140/90 mmHg","description":"To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.8","spread":null},{"groupId":"OG001","value":"-12.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.8","spread":null},{"groupId":"OG001","value":"-14.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Vital Signs (Heart Rate)","description":"To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"10.07"},{"groupId":"OG001","value":"0.4","spread":"8.89"}]}]}]},{"type":"PRIMARY","title":"ECGs","description":"To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"67","spread":null}]},{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"8","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"67","spread":null}]},{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"8","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Measures, Urine Test Results (Any Marked Abnormality)","description":"To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Vital Signs (Blood Pressure)","description":"To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"11.41"},{"groupId":"OG001","value":"-2.9","spread":"12.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"8.21"},{"groupId":"OG001","value":"-1.0","spread":"7.89"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":76},"commonTop":["NASOPHARYNGITIS","GASTROENTERITIS","PHARYNGITIS","POLLAKIURIA","KETOSIS"]}}}